Mitochondrial Disease

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Abliva
AblivaSweden - Lund
1 program
1
KL1333Phase 11 trial
Active Trials
NCT04643249Completed14Est. Dec 2020
R
RibonovaPA - Wynnewood
1 program
ProbucolN/A1 trial
Active Trials
NCT06931834Available
PTC Therapeutics
1 program
VatiquinoneN/A1 trial
Active Trials
NCT07159139Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AblivaKL1333

Clinical Trials (3)

Total enrollment: 14 patients across 3 trials

Drug-drug Interaction Study of KL1333 in Healthy Subjects

Start: Nov 2020Est. completion: Dec 202014 patients
Phase 1Completed

Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease

N/AAvailable

Vatiquinone Expanded Access Protocol

N/AAvailable

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space